189 related articles for article (PubMed ID: 34210800)
1. Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts.
Schlüter M; Oswald E; Winklmeier S; Meinl I; Havla J; Eichhorn P; Meinl E; Kümpfel T
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34210800
[TBL] [Abstract][Full Text] [Related]
2. Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS.
Largey F; Jelcic I; Sospedra M; Heesen C; Martin R; Jelcic I
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31554671
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Warnke C; Stettner M; Lehmensiek V; Dehmel T; Mausberg AK; von Geldern G; Gold R; Kümpfel T; Hohlfeld R; Mäurer M; Stangel M; Straeten V; Limmroth V; Weber T; Kleinschnitz C; Wattjes MP; Svenningsson A; Olsson T; Hartung HP; Hermsen D; Tumani H; Adams O; Kieseier BC
Mult Scler; 2015 Jul; 21(8):1036-44. PubMed ID: 25392339
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Selter RC; Biberacher V; Grummel V; Buck D; Eienbröker C; Oertel WH; Berthele A; Tackenberg B; Hemmer B
Mult Scler; 2013 Oct; 19(11):1454-61. PubMed ID: 23439578
[TBL] [Abstract][Full Text] [Related]
5. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
Auer M; Borena W; Holm-von Laer D; Deisenhammer F
J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
[TBL] [Abstract][Full Text] [Related]
6. Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients.
Stich O; Kluge J; Speck J; Rauer S
Acta Neurol Scand; 2015 Jun; 131(6):381-8. PubMed ID: 25402869
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
[TBL] [Abstract][Full Text] [Related]
8. Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
Kivisäkk P; Francois K; Mbianda J; Gandhi R; Weiner HL; Khoury SJ
PLoS One; 2014; 9(7):e103716. PubMed ID: 25075741
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis.
Cuculiza Henriksen A; Ammitzbøll C; Petersen ER; McWilliam O; Sellebjerg F; von Essen MR; Romme Christensen J
Mult Scler Relat Disord; 2021 Jul; 52():102987. PubMed ID: 33984651
[TBL] [Abstract][Full Text] [Related]
10. Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production.
Persson L; Longhi S; Enarsson J; Andersen O; Haghigi S; Nilsson S; Lagging M; Johansson M; Bergström T
J Clin Virol; 2014 Sep; 61(1):107-12. PubMed ID: 25022622
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
Kowarik MC; Astling D; Lepennetier G; Ritchie A; Hemmer B; Owens GP; Bennett JL
Neurotherapeutics; 2021 Jan; 18(1):364-377. PubMed ID: 33258072
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
Cobo-Calvo Á; Figueras A; Bau L; Matas E; Mañé Martínez MA; León I; Majòs C; Romero-Pinel L; Martínez-Yélamos S
Clin Immunol; 2016 Oct; 171():18-24. PubMed ID: 27496090
[TBL] [Abstract][Full Text] [Related]
13. A comparison of measles-rubella-zoster reaction, oligoclonal IgG bands, oligoclonal kappa free light chains and kappa index in multiple sclerosis.
Zondra Revendova K; Svub K; Bunganic R; Pelisek O; Volny O; Ganesh A; Bar M; Zeman D; Kusnierova P
Mult Scler Relat Disord; 2024 Jan; 81():105125. PubMed ID: 37980789
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
[TBL] [Abstract][Full Text] [Related]
15. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study.
Mancuso R; Franciotta D; Rovaris M; Caputo D; Sala A; Hernis A; Agostini S; Calvo M; Clerici M
Mult Scler; 2014 Dec; 20(14):1900-3. PubMed ID: 24948690
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
[TBL] [Abstract][Full Text] [Related]
17. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis.
Deslandes MQ; Alves PT; Alvarenga MP; Lessa VCC; Camargo S; Alvarenga RMP; Vasconcelos CC
Clin Ther; 2020 Jul; 42(7):1292-1301. PubMed ID: 32593474
[TBL] [Abstract][Full Text] [Related]
19. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K
Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755
[TBL] [Abstract][Full Text] [Related]
20. Modification of CSF findings in multiple sclerosis in the era of rapidly expanding treatment options.
Giotaki I; Lange P; Weber MS
Expert Rev Neurother; 2019 Mar; 19(3):277-283. PubMed ID: 30786785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
